Combination therapy for cancer treatment

A method of treating a patient with cancer and having a tumor, the method comprising

• i) administering to the patient an effective amount of liposomal irinotecan, wherein the liposomal irinotecan is a unilamellar lipid bilayer vesicle, which encapsulates irinotecan sucrosofate salt and the vesicle is composed of 1,2-distearoyl-sn-glycero-3-phosphochline, cholesterol, and methoxy-terminated polyethylene glycol(MW 2000)-distearoylphosphatidylethanolamine, at a weight ratio of 6.81 mg:2.22 mg:0.12 mg;
• and
• ii) administering to the patient an effective amount of a PARP inhibitor selected from the group consisting of niraparib, olaparib, veliparib, rucaparib and talazoparib, wherein the PARP inhibitor is administered after an effective irinotecan plasma clearing interval, wherein the patient has been diagnosed with ovarian cancer.

A method of treating a patient diagnosed with ovarian cancer and having a solid tumor, the method comprising administering to the patient an antineoplastic therapy in a 28-day treatment cycle, the antineoplastic therapy consisting of:

• i) intravenously administering to the patient an effective amount of a liposomal irinotecan only on days 1 and 15 of the treatment cycle, the liposomal irinotecan having an irinotecan terminal elimination half-life of about 26.8 hours and a maximal irinotecan plasma concentration of about 38.0 micrograms/ml;
• and
• ii) administering an effective amount of a PARP inhibitor to the patient on days 5-12 and 19-25 or 3-12 and 17-25 of the treatment cycle.